PBHは3Qの収益予測を上回り 2026年の予測を上げ 株価は堅調な結果にもかかわらず下落した PBH beat Q3 earnings estimates, raised 2026 guidance, and shares dipped despite strong results.

Prestige Consumer Healthcare (PBH) は2025年第3四半期に株当たり1.07ドルで,推定値を0.10ドル上回り,274.11百万ドルの収益を報告し,前年比3.4%の減少にもかかわらず,予想を上回った. Prestige Consumer Healthcare (PBH) reported Q3 2025 earnings of $1.07 per share, beating estimates by $0.10, and revenue of $274.11 million, exceeding expectations despite a 3.4% year-over-year decline. 会社は2026年度の完全EPSガイドを440-480ドルに上げた. The company raised its 2026 full-year EPS guidance to $4.540–$4.580. 株価は59.85ドルで閉店し,1.5"ドル下落し,総評は"持参"で,目標価格は85.33ドルだった. Shares closed at $59.85, down $1.51, with a "Hold" consensus rating and a target price of $85.33. 同社は,北米及び国際OTC医療機関で活動しており,強いマージンと流動性を維持している. The firm operates in North American and international OTC healthcare, maintaining strong margins and liquidity.